Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33508
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGupta, Ruta-
dc.contributor.authorSelinger, Christina I-
dc.contributor.authorAshford, Bruce-
dc.contributor.authorChua, Margaret S T-
dc.contributor.authorClark, Jonathan R-
dc.contributor.authorDamian, Diona L-
dc.contributor.authorJackett, Louise A-
dc.contributor.authorJames, Craig-
dc.contributor.authorJohnson, Stuart-
dc.contributor.authorLadwa, Rahul-
dc.contributor.authorLambie, Duncan-
dc.contributor.authorMcKenzie, Catriona-
dc.contributor.authorTan, Swee T-
dc.contributor.authorScolyer, Richard A-
dc.date2023-
dc.date.accessioned2023-08-16T05:31:27Z-
dc.date.available2023-08-16T05:31:27Z-
dc.date.issued2023-10-
dc.identifier.citationPathology 2023-10; 55(6)en_US
dc.identifier.issn1465-3931-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33508-
dc.description.abstractNon-melanocytic skin cancers (NMSCs) account for five times the incidence of all other cancers combined and cost US $6 billion annually. These are the most frequent specimens encountered in community pathology practice in many Western countries. Lack of standardised structured pathology reporting protocols (SPRPs) can result in omission of critical information or miscommunication leading to suboptimal patient management. The lack of standardised data has significant downstream public health implications, including insufficient data for reliable development of prognostic tools and health-economy planning. The Royal College of Pathologists of Australasia has developed an NMSC SPRP. A multidisciplinary expert committee including pathologists, surgeons, dermatologists, and radiation and medical oncologists from high volume cancer centres was convened. A systematic literature review was performed to identify evidence for including elements as mandatory standards or best practice guidelines. The SPRP and accompanying commentary of evidence, definitions and criteria was peer reviewed by external stakeholders. Finally, the protocol was revised following feedback and trialled in multiple centres prior to implementation. Some parameters utilised clinically for determining management and prognosis including tumour depth, lymphovascular invasion or distance to the margins lack high level evidence in NMSC. Dermatologists, surgeons, and radiation oncologists welcomed the SPRP. Pathologists indicated that the variety of NMSC specimens ranging from curettes to radical resections as well as significant differences in the biological behaviour of different tumours covered by the NMSC umbrella made use of a single protocol difficult. The feedback included that using a SPRP for low risk NMSC was neither clinically justified nor compensated adequately by the Australian Medicare Reimbursement Schedule. Following stakeholder feedback, the SPRP implementation was restricted to excision specimens of head and neck NMSC; and low-risk NMSC, such as superficial basal cell carcinoma, were excluded. Implementing NMSC SPRP fulfils an unmet clinical need. Unlike other cancers, NMSCs generate a range of specimen types and are reported in a wide range of pathology practices. Limiting use of SPRP to NMSC at higher risk of progression and providing formatted templates for easy incorporation into laboratory information systems were essential to successful deployment. In the future, further consideration should be given to implementing the SPRP to include all relevant specimens, including non-head and neck and low-risk NMSC specimens.en_US
dc.language.isoeng-
dc.subjectBasal cell carcinomaen_US
dc.subjectcutaneousen_US
dc.subjectdepth of invasionen_US
dc.subjectlymphovascular invasionen_US
dc.subjectmacroscopicen_US
dc.subjectmarginsen_US
dc.subjectmicroscopicen_US
dc.subjectnon-melanocytic skin cancersen_US
dc.subjectperineural invasionen_US
dc.subjectsquamous cell carcinomaen_US
dc.subjectstructured reporting protocolen_US
dc.titleImplementing structured pathology reporting protocol for non-melanocytic skin cancers: practical considerations.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitlePathologyen_US
dc.identifier.affiliationFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, NSW, Australia.en_US
dc.identifier.affiliationRoyal College of Pathologists of Australasia, Sydney, NSW, Australia.en_US
dc.identifier.affiliationIllawarra Health and Medical Research Institute, Wollongong, NSW, Australia; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, NSW, Australia; Illawarra and Shoalhaven Local Health District, Wollongong, NSW, Australia; School of Medicine, University of Wollongong, Wollongong, NSW, Australia.en_US
dc.identifier.affiliationDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Vic, Australia.en_US
dc.identifier.affiliationDepartment of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, NSW, Australia; Royal Prince Alfred Institute of Academic Surgery, Sydney Local Health District, Sydney, NSW, Australia; Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.en_US
dc.identifier.affiliationDiscipline of Dermatology, Bosch Institute, University of Sydney, and Royal Prince Alfred Hospital Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.en_US
dc.identifier.affiliationPathologyen_US
dc.identifier.affiliationMile End, Adelaide, SA, Australia.en_US
dc.identifier.affiliationWellington SCL, Hutt Valley Hospital Site, New Zealand.en_US
dc.identifier.affiliationDepartment of Cancer Care Services, Princess Alexandra Hospital, Woolloongabba, Qld, Australia; Faculty of Medicine, University of Queensland, Herston, Qld, Australia.en_US
dc.identifier.affiliationPrincess Alexandra Hospital, Pathology Queensland, Brisbane, Qld, Australia; Frazer Institute, University of Queensland, Brisbane, Qld, Australia.en_US
dc.identifier.affiliationFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, NSW, Australia.en_US
dc.identifier.affiliationGillies McIndoe Research Institute, Wellington, New Zealand; Wellington Regional Plastic, Maxillofacial and Burns Unit, Hutt Hospital, Wellington, New Zealand; Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Vic, Australia.en_US
dc.identifier.affiliationFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.en_US
dc.identifier.doi10.1016/j.pathol.2023.07.003en_US
dc.type.contentTexten_US
dc.identifier.pubmedid37573165-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptAnatomical Pathology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

42
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.